Combination Therapy Using SCD1 and PD1 Inhibitors to Treat Cancer

Technology #2017-036

Mayo Clinic has discovered that inhibition of stearoyl-CoA desaturase 1, SCD1 - a key enzyme fatty acid metabolism, in combination with PD1/PD-L1 inhibition enhances T cell based cancer immunotherapy.